dcsimg

ag真人平台官方

Global Offering

ag真人平台官方: 

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. (09989)
 
 
► Cover
► ag真人平台官方:Important
► ag真人平台官方:Expected Timetable
► Contents
► Summary
► ag真人平台官方:Definitions
► ag真人平台官方:Glossary of Technical Terms
► ag真人平台官方:Forward-looking Statements
► ag真人平台官方:Risk Factors
► Waivers and Consents from Strict Compliance with the Hong Kong Listing Rules
► Information about this Prospectus and the Global Offering
► Directors, Supervisors and Parties Involved in the Global Offering
► ag真人平台官方:Corporate Information
► ag真人平台官方:Industry Overview
► ag真人平台官方:Regulatory Environment
► ag真人平台官方:History, Development and Corporate Structure
► Business
► ag真人平台官方:Relationship with the Controlling Shareholders
► ag真人平台官方:Connected Transaction
► ag真人平台官方:Directors, Supervisors and Senior Management
► ag真人平台官方:Share Capital
► ag真人平台官方:Substantial Shareholders
► ag真人平台官方:Cornerstone Investors
► ag真人平台官方:Financial Information
► ag真人平台官方:Future Plans and Use of Proceeds
► ag真人平台官方:Underwriting
► ag真人平台官方:Structure of the Global Offering
► ag真人平台官方:How to Apply for the Hong Kong Offer Shares
► ag真人平台官方:Appendix I - Accountants' Report
► Appendix IA - Report on Review of Interim Condensed Consolidated Financial Information for the Three Months Ended March 31, 2020
► Appendix II - Unaudited Pro Forma Financial Information
► Appendix III - Taxation and Foreign Exchange
► Appendix IV - Summary of Principal Legal and Regulatory Provisions
► ag真人平台官方:Appendix V - Summary of Articles of Association
► ag真人平台官方:Appendix VI - Statutory and General Information
► Appendix VII - Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection
► ag真人平台官方:Back Cover